Journal of Clinical Lipidology
Volume 2, Issue 4 , Pages 267-273 , August 2008

The importance of non–HDL cholesterol reporting in lipid management

  • Michael J. Blaha, MD, MPH

      Affiliations

    • The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA
    • ,
  • Roger S. Blumenthal, MD

      Affiliations

    • The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA
    • ,
  • Eliot A. Brinton, MD

      Affiliations

    • University of Utah School of Medicine, 420 Chipeta Way, Rm 1160, Salt Lake City, UT, 84108 USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Terry A. Jacobson, MD

      Affiliations

    • Emory University, Atlanta, GA, USA
    • ,
  • National Lipid Association Taskforce on Non-HDL Cholesterol

      Affiliations

    • The members of the National Lipid Association Taskforce on Non-HDL Cholesterol are: Roger Blumenthal, MD, Eliot Brinton, MD, John R. Crouse, MD, Michael H. Davidson, MD, Anne C. Goldberg, MD, Terry Jacobson, MD, Peter H. Jones, MD, John Kostis, MD, James McKenney, PharmD, Neil J. Stone, MD, Dan Wise, MD, Janet Long, MSN, David Capuzzi, MD, and Maria Lopes-Virella, MD.

Received 18 June 2008 ,Accepted 24 June 2008.

References 

  1. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512–1524
  2. Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. 2007;50:1735–1741
  3. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol. 2002;90(suppl):22i–29i
  4. Kwiterovich PO. Clinical relevance of the biochemical, metabolic and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol. 2002;90(suppl):30i–45i
  5. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486–2497
  6. Mora S, Szklo M, Otvos J, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;192:211–217
  7. Austin MA, King M-C, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495–506
  8. Grundy SM. Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. Arch Intern Med. 2001;161:1379–1380
  9. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–458
  10. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Non–high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98:1363–1368
  11. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641–651
  12. Abate N, Vega GL, Grundy SM. Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100. Atherosclerosis. 1993;104:159–171
  13. Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety Study (Correlation of non–high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels). Am J Cardiol. 2001;88:265–269
  14. Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care. 1990;13:153–169
  15. Frost PH, Havel RJ. Rationale for use of non–high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol. 1998;81(suppl):26B–31B
  16. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447–459
  17. Sattar N, Williams K, Sniderman AD, D'Agostino R, Haffner SM. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation. 2004;110:2687–2693
  18. Krauss RM, Siri PW. Metabolic abnormalities: triglyceride and low-density lipoprotein. Endocrinol Metab Clin North Am. 2004;33:405–415
  19. Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413–1419
  20. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G Bypass Angioplasty Revascularization Investigation. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106:2537–2542
  21. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care. 2003;26:16–23
  22. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28(8):1916–1921
  23. Ridker PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326–333
  24. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298:776–785
  25. Orakzai SH, Nasir K, Blaha M, Blumenthal RS, Raggi P, et al. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis. 2008;Mar 25. [Epub ahead of print.]
  26. Kawamoto R, Oka Y, Tomita H, Kodama A. Non-HDL cholesterol as a predictor of carotid atherosclerosis in the elderly. J Atheroscler Thromb. 2005;12:143–148
  27. Cromwell WC, Otvos JD. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep. 2004;6:381–387
  28. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins versus lipids as indices of coronary risk and as targets of statin treatment. Lancet. 2003;361:777–780
  29. Sacks FM. The apolipoprotein story. Atherosclerosis. 2006;7(suppl):23–27
  30. Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec Cardiovascular Study. Circulation. 1996;94:23–28
  31. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358:2026–2033
  32. Friedewald WT, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein in plasma without use of preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  33. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556–563

PII: S1933-2874(08)00274-2

doi: 10.1016/j.jacl.2008.06.013

Journal of Clinical Lipidology
Volume 2, Issue 4 , Pages 267-273 , August 2008

Article Tools

* Image Usage & Resolution